We use cookies to ensure that we give you the best experience on our website Learn more

May 28, 2018

ESPID 2018

03 / DIFFERENT CLINICAL MANIFESTATIONS AND ANTIVIRAL-RESPONSE BETWEEN INFLUENZA SUBTYPES

;

Caballero, M.;

Urraca-Camps, S.;

Jordan, I.;

García-García, J.J.;

Launes, C.

influenza

antiviral

Abstract

Abstract

thumbnail

Keywords

influenza

antiviral

Abstract

Background Several observational studies demonstrated that Oseltamivir had a beneficial effect during 2009-A/H1N1 pandemics, but there are still controversies with seasonal subtypes (A/H3N2 and B). Methods The aim of this observational retrospective study was to detect clinical and antiviral-response differences among the current circulating viral subtypes during two consecutive seasons (2015/16-2016/17). Seventy-five hospitalized patients were recruited in a tertiary hospital: 25 influenza A/H1N1-2009, 25 A/H3N2 and 25 influenza B. All patients received oseltamivir. Results Children with influenza-B infection were older than those with A/H1N1 and A/H3N2 (168 months (p25-27: 59-196) vs 39 (18-64) and 27 (16-85), respectively; p<0.01). 45/75 had preexisting conditions, mainly neurological. Rates of pre-existing conditions did not differ between subtypes. The leading cause of hospitalization was respiratory insufficiency (39/75), with similar proportion between the groups. Digestive manifestations were frequent (24/75), but diarrhea was only described in A/H1N1 (5/25;p=0.03). Neurological symptoms tended to be more frequent in patients with influenza A (11/50 A vs 1/25 B;p=0.06). Acute myositis only occurred with influenza B infection (5/25;p<0.01). Bacterial co-infection (mainly pneumococcal) was more frequent in patients with influenza A (11/50 vs 1/25;p=0.06). 9/75 patients required intensive-care. No differences between subtypes were found. Nevetheless, none of the 5/9 previously healthy patients had influenza B. No mortality was found. There was a correlation between the delay in starting oseltamivir treatment and the duration of the disease for all subtypes (rho-Spearman A/H1N1:0.58, p<0,01; A/H3N2:0.51, p=0,01; B:0.49, p=0,04). Conclusions Extra-pulmonary symptoms and severity of influenza disease may vary depending on the subtype, especially in previously-healthy patients. Delays in starting oseltamivir treatment increased length of symptoms, regardless of the subtype.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.